ERBB2 and cancer: The prevalence of TP53 mutations is higher among the hormone receptor-positive and HER2-positive subtypes in our cohort compared to non-Asian premenopausal cancers in TCGA, along with elevated frequencies of TET2 and CDK12 mutations among hormone receptor-positive patients.